Video

Dr. Shah and Dr. Wang on Navigating the Referral Process for CAR T-Cell Therapy in Hematologic Malignancies

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, and Michael Wang, MD, professor, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Referring patients for CAR T-cell therapy can be a challenging process, Shah explains. Patients who receive CAR T-cell therapy are expected to stay in or around the treatment center for 2 to 4 weeks, depending on the severity of CAR T-cell therapy–related toxicities, Wang says.

Ultimately, close collaboration between community and academic practices is needed to ensure the referral process is optimal for patients, Shah and Wang conclude.

Related Videos
Sheldon M. Feldman, MD
Louis Crain Garrot, MD
Michel Delforge, MD, PhD
Thach-Giao Truong, MD
Aparna Parikh, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Janaki Neela Sharma, MD
Matthew Powell, MD
Noman Ashraf, MD
Sheldon M. Feldman, MD